ReviewJournal of pharmaceutical analysis2026
Halogenated anthraquinones in breast cancer therapy: Structural modifications targeting VEGF-related angiogenesis pathways.
Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Halogenated anthraquinone derivatives have good potential in addressing the major clinical challenges associated with anthracyclines for breast cancer, including high toxicity, low selectivity, and drug resistance issues. By analyzing the structure-activity relationships of these compounds, the review highlights how specific structural modifications may enhance therapeutic efficacy. A comprehensive overview is also provided to categorize breast cancer progression across stages 0 to IV, along with therapeutic approaches for each of the three basic molecular subtypes, with placing particular focus on triple-negative breast cancer. This review details how anthraquinone derivatives modulate the vascular endothelial growth factor (VEGF)-related signaling pathways and regulate the expression of key proteins and chemokines, thereby inhibiting endothelial cell function during tumor angiogenesis, suppressing cancer cell migration and immune evasion in breast cancer. Studies on halogenated anthraquinone derivatives in anticancer applications between 2013 and 2025 are summarized, and the cutting-edge therapeutic strategies that have contributed to the development of anthraquinone derivatives are highlighted. The high approval rate of halogen-containing drugs released by the U.S. Food and Drug Administration in 2024, alongside their promising therapeutic efficacy in oncology, has once again drawn the attention of researchers. Overall, the contributions of halogen substitution to molecular stability, target specificity, and resistance to metabolic degradation highlight the significant potential of halogenated anthraquinone derivatives in the development of novel therapeutics for breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.